X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14728) 14728
Dissertation (63) 63
Book Chapter (22) 22
Magazine Article (21) 21
Publication (12) 12
Newspaper Article (6) 6
Paper (4) 4
Reference (4) 4
Conference Proceeding (2) 2
Web Resource (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atorvastatin (10343) 10343
humans (8744) 8744
male (6302) 6302
female (5158) 5158
statins (4968) 4968
atorvastatin calcium (4490) 4490
middle aged (4370) 4370
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (3524) 3524
aged (3327) 3327
cholesterol (2929) 2929
simvastatin (2879) 2879
cardiac & cardiovascular systems (2853) 2853
pharmacology & pharmacy (2643) 2643
pyrroles - therapeutic use (2640) 2640
heptanoic acids - therapeutic use (2637) 2637
animals (2406) 2406
treatment outcome (2191) 2191
adult (2170) 2170
pravastatin (1766) 1766
atherosclerosis (1763) 1763
risk factors (1745) 1745
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (1700) 1700
pyrroles - pharmacology (1693) 1693
heptanoic acids - pharmacology (1688) 1688
cholesterol, ldl - blood (1624) 1624
risk (1549) 1549
anticholesteremic agents - therapeutic use (1507) 1507
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (1446) 1446
prevention (1433) 1433
peripheral vascular disease (1414) 1414
therapy (1410) 1410
lipids (1388) 1388
pyrroles - administration & dosage (1335) 1335
heptanoic acids - administration & dosage (1333) 1333
inflammation (1251) 1251
rosuvastatin (1244) 1244
medicine, general & internal (1235) 1235
hypercholesterolemia (1234) 1234
coronary-heart-disease (1192) 1192
statin (1188) 1188
rats (1171) 1171
hypercholesterolemia - drug therapy (1164) 1164
disease (1100) 1100
analysis (1085) 1085
dose-response relationship, drug (1059) 1059
antilipemic agents (1044) 1044
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (1035) 1035
cardiovascular disease (1002) 1002
mortality (971) 971
cardiovascular diseases (947) 947
efficacy (942) 942
care and treatment (932) 932
cardiovascular (924) 924
c-reactive protein (917) 917
time factors (916) 916
drug therapy (900) 900
drug therapy, combination (899) 899
cardiovascular-disease (888) 888
research (875) 875
myocardial-infarction (861) 861
prospective studies (844) 844
expression (843) 843
abridged index medicus (842) 842
double-blind method (842) 842
safety (821) 821
cholesterol - blood (816) 816
statin therapy (810) 810
mice (788) 788
events (777) 777
simvastatin - therapeutic use (773) 773
oxidative stress (740) 740
diabetes (726) 726
coronary heart disease (721) 721
lipids - blood (709) 709
aged, 80 and over (699) 699
low density lipoproteins (693) 693
follow-up studies (690) 690
cardiovascular diseases - prevention & control (689) 689
ezetimibe (686) 686
medicine, research & experimental (685) 685
metaanalysis (681) 681
anticholesteremic agents - administration & dosage (673) 673
triglycerides - blood (670) 670
cardiovascular agents (666) 666
pyrroles - adverse effects (641) 641
rosuvastatin calcium (640) 640
heptanoic acids - adverse effects (639) 639
biochemistry & molecular biology (631) 631
cholesterol, hdl - blood (628) 628
hypertension (616) 616
anticholesteremic agents - pharmacology (612) 612
biomarkers - blood (607) 607
endocrinology & metabolism (595) 595
retrospective studies (594) 594
health aspects (593) 593
hyperlipidemias - drug therapy (591) 591
dyslipidemia (584) 584
randomized controlled trials as topic (582) 582
stroke (575) 575
cardiology (572) 572
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14176) 14176
Russian (191) 191
Spanish (168) 168
Chinese (144) 144
German (141) 141
Japanese (121) 121
French (105) 105
Portuguese (87) 87
Polish (30) 30
Korean (27) 27
Persian (25) 25
Hungarian (21) 21
Turkish (19) 19
Italian (13) 13
Swedish (9) 9
Dutch (7) 7
Norwegian (7) 7
Ukrainian (7) 7
Czech (6) 6
Danish (4) 4
Croatian (3) 3
Lithuanian (2) 2
Serbian (2) 2
Slovenian (2) 2
Belarusian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International heart journal, ISSN 1349-2365, 2019
The initiation and progression of atherosclerotic cardiovascular disease (ASCVD) has always been associated with a series of risk factors. Evidences of statin... 
Atorvastatin
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2018, Volume 72, Issue 16, pp. C174 - C175
Journal Article
Drug Development and Industrial Pharmacy, ISSN 1520-5762, 2014, Volume 41, Issue 4, pp. 594 - 604
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10088, pp. 2473 - 2481
Summary Background In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | CLINICAL-TRIALS | CARDIOVASCULAR-DISEASE | PREVENTION | RISK | INTOLERANCE | PARTICIPANTS | Hematologic Diseases - chemically induced | Hypolipidemic Agents - adverse effects | Atorvastatin - adverse effects | Double-Blind Method | Nocebo Effect | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Atorvastatin - administration & dosage | Sleep Wake Disorders | Early Termination of Clinical Trials | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Lymphatic Diseases - chemically induced | Hypolipidemic Agents - administration & dosage | Hypertension - complications | Adult | Female | Hypercholesterolemia - prevention & control | Aged | Muscular Diseases - chemically induced | Clinical trials | Medicine, Experimental | Complications and side effects | Medical research | Epidemiology | Statins | Analysis | Cardiac patients | Sexual disorders | Risk factors | Myocardial infarction | Heart | Therapy | Laboratories | Funding | Physicians | Disorders | Impairment | Cognitive ability | Lipids | Cardiovascular disease | Angina | Evidence-based medicine | Matching | Connective tissues | Disturbance | Heart diseases | Public health | Hypertension | Medical personnel | Lymphatic system | Fasting | Effectiveness | Kidneys | Health risks | Erectile dysfunction | Risk analysis | Patients | Low density lipoprotein | Cholesterol | Doctors | Side effects | Sleep | Atorvastatin | Infarction | Health risk assessment | Cardiovascular diseases | Kidney transplantation | Clinical Medicine | management | clinical-trials | intolerance | risk | cardiovascular-disease | Klinisk medicin | General & Internal Medicine | prevention | participants
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2016, Volume 315, Issue 9, pp. 877 - 888
Journal Article
Nature communications, ISSN 2041-1723, 2019, Volume 10, Issue 1, pp. 498 - 13
Journal Article
Journal Article
Journal of controlled release, ISSN 0168-3659, 05/2017, Volume 254, pp. 10 - 22
Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor systemic availability (14%) after oral administration in addition to other side... 
Atorvastatin calcium | Transdermal delivery | Oxidative stress | Nanotransfersomes | Hyperlipidemia | Liver toxicity | LASER-SCANNING MICROSCOPY | DRUG-DELIVERY | ULTRADEFORMABLE LIPOSOMES | DEPENDENT PATHWAYS | CARRIERS | CHEMISTRY, MULTIDISCIPLINARY | EDGE ACTIVATORS | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | SKIN | IN-VIVO EVALUATION | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Lecithins - metabolism | Polysorbates - chemistry | Rats, Wistar | Atorvastatin Calcium - administration & dosage | Biological Availability | Male | Polyethylene Glycols - chemistry | Administration, Cutaneous | Hydroxymethylglutaryl-CoA Reductase Inhibitors - chemistry | Nanocapsules - chemistry | Cholesterol - chemistry | Atorvastatin Calcium - toxicity | Lecithins - chemistry | Liver - drug effects | Esters - chemistry | Glycerol - analogs & derivatives | Glycerol - chemistry | Polyethylene Glycols - metabolism | Transdermal Patch | Glycerides - chemistry | Fatty Acids - chemistry | Hydroxymethylglutaryl-CoA Reductase Inhibitors - toxicity | Hyperlipidemias - drug therapy | Atorvastatin Calcium - chemistry | Skin Absorption | Permeability | Chemistry, Pharmaceutical | Particle Size | Animals | Poloxamer | Drug Liberation | Hyperlipidemias - chemically induced | Drug Delivery Systems - methods | Esters | Polyethylene glycol | Fatty acids | Liver | Transdermal medication | Membrane lipids | Enzymes | Low density lipoproteins
Journal Article
Cochrane library, ISSN 1465-1858, 2016, Volume 2017, Issue 3, p. CD009753
Journal Article
Medicine (Baltimore), ISSN 0025-7974, 08/2018, Volume 97, Issue 31, p. e11718
Journal Article
Journal Article